Certified by Founder
Lodge
DalCor Pharmaceuticals
start up
Canada
- Montreal, Québec
- 22/09/2023
- Series D
- $80,000,000
DalCor Pharmaceuticals: DalCor Pharmaceuticals is pioneering precision medicine for patients with cardiovascular disease. By combining genetic and clinical insights, the company’s development program, dalcetrapib, is intended to reduce fatal and non-fatal myocardial infarction (MI) following a recent acute coronary syndrome and deliver superior cardiovascular outcome in a specific genetic subset of patients.
- Industry Biotechnology Research
- Website https://dalcorpharma.com/
- LinkedIn https://www.linkedin.com/company/dalcor-pharmaceuticals/about/
Yuzu | $35,000,000 | (Apr 7, 2026)
Moonbounce | $12,000,000 | (Apr 7, 2026)
Insight Health AI, Inc. | $11,000,000 | (Apr 7, 2026)
Ridge AI | $2,600,000 | (Apr 7, 2026)
NeuBird AI | $19,300,000 | (Apr 7, 2026)
Stipple Bio | $100,000,000 | (Apr 7, 2026)
Noon | $44,000,000 | (Apr 7, 2026)
Miravoice | $6,300,000 | (Apr 7, 2026)
Numos | $4,250,000 | (Apr 3, 2026)
Alien | $7,100,000 | (Apr 3, 2026)
EnerVenue | $300,000,000 | (Apr 3, 2026)
Monarch Quantum | $55,000,000 | (Apr 3, 2026)